Biogenerics and New Technologies Compete with 1st Generation Major Products
Summary
Company Overview Contact Info & Offices Press Releases La Merie Business Intelligence Press Release Receive press releases from La Merie Business Intelligence: By Email RSS Feeds: Biogenerics and New Technologies Compete with 1st Generation Major Products The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions.Sign up for a free copy of the R&D Newsletter at www.pipelinereview.com/newsletter About PipelineReview.com PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry.Although estimated price cuts of 25 to 30 % will be less than those for small molecule generics, cost pressure in the health care markets will support acceptance of biogeneric products.The pipeline evaluation includes the market description of the first generation products and a compilation of next generation projects, drug delivery solutions, protein engineering approaches, orally available small molecules and biogeneric projects in Western countries as well as in countries with insufficient patent protection.About FREE R&D NewsletterThe daily Newsletter from Europe provides a selection of the most interesting news from biopharmaceutical R&D and information about partnering opportunites and company profiles.Sign up for a free copy of the R&D Newsletter at www.pipelinereview.com/newsletterAbout PipelineReview.comPipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on R&D in the Biopharmaceutical Industry.